Novo Nordisk (NVO.US) is planning to initiate a study on the potential use of GLP-1 drugs for addiction treatment.

Market IntelThursday, Mar 6, 2025 8:00 am ET

1min read

Novo Nordisk (NVO.US) R&D head Martin Holst Lange said during an online meeting on Thursday that the company plans to conduct a study to examine how its GLP-1 weight loss/diabetes drugs can help people overcome addictions to smoking, drinking, shopping, and even nail-biting.The company's GLP-1 portfolio includes semaglutide (an injectable weight loss drug marketed as Wegovy) and Ozempic (for the treatment of type 2 diabetes). The company also received FDA approval to market semaglutide to reduce the risk of serious heart problems in overweight or obese adults and to reduce the risk of kidney disease worsening. Later-stage studies are also ongoing to test its potential to treat early Alzheimer's disease."We will further investigate this and explore how we can help patients with GLP-1 addiction. This must be solved in a scientific way, and of course, also from a regulatory perspective, in a very strict way, so we can really see the potential of GLP-1 in this field," Lange said.

Disclaimer: the above is a summary showing certain market information. AInvest is not responsible for any data errors, omissions or other information that may be displayed incorrectly as the data is derived from a third party source. Communications displaying market prices, data and other information available in this post are meant for informational purposes only and are not intended as an offer or solicitation for the purchase or sale of any security. Please do your own research when investing. All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Keep in mind that while diversification may help spread risk, it does not assure a profit, or protect against loss in a down market.